Vienna Vascular Liver Disease Study

Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank

The aim of this Register Trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases. Furthermore, important clinical parameters will be assessed in order to evaluate patients' coagulation status and in order to develop new biomarkers derived from blood, urine, stool or ascites of patients as well as histological samples from the upper / lower GI-tract or the liver in order to better understand the natural history of vascular liver diseases.

We will include patients with vascular liver diseases, including

• portal vein thrombosis (PVT)
• Budd-Chiari Syndrome (BCS)
• Heredetary Hemorrhagic Teleangiectasia (HHT, or Osler-Rendu Disease)
• Noncirrhotic-portal hypertension (NCPH) and Porto-sinusoidal vascular disorder
• Cirrhosis cardiaque if the fulfill inclusion/exclusion criteria and provide written informed consent. Participation in the biobank is optional for the patients. In particular, we will study the natural course of the patients in regard to hepatic decompensation (ascites, variceal bleeding, hepatic encephalopathy), need for intensified treatment (TIPS, ICU, liver transplantation) and survival.

Inclusion Criteria:

• Diagnosis of a vascular liver disease by imaging (sonography, CT, MRI), transient elastography or liver histology
• PVT: Portal vein thrombosis
• NCPH: non-cirrhotic Portal Hypertension
• PSVD: porto-sinusoidal vascular disorder
• BCS: Budd-Chiari-Syndrome
• SOS: sinusoidal occlusive disease
• HHT: hereditary hemorrhagic teleangiectasia
• CIRCAD: cirrhosis cardiaque
• Age >18 years and <100 years
• Written informed consent obtained

Exclusion Criteria:

- withdrawal of written informed consent